Skip to main content

Table 5 Quality of Studies Included

From: Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a systematic literature review

Citation

Data Quality a

Scientific Method b

Overall Quality Rating

Anders et al., 2011 [15]

Sufficient

Sufficient

Sufficient

Witzel et al., 2018 [16]

Sufficient

Sufficient

Sufficient

Ahn et al., 2013 [17]

Sufficient

Insufficient

Sufficient

Yap et al., 2012 [18]

Sufficient

Sufficient

Sufficient

Mounsey et al., 2018 [20]

Sufficient

Sufficient

Sufficient

Duchnowska et al., 2012 [21]

Sufficient

Insufficient

Sufficient

Duchnowska et al., 2009 [22]

Sufficient

Insufficient

Sufficient

Duchnowska et al., 2015 [23]

Sufficient

Sufficient

Sufficient

Gori et al., 2019 [24]

Sufficient

Sufficient

Sufficient

Hayashi et al., 2015 [25]

Sufficient

Sufficient

Sufficient

Maurer et al., 2018 [26]

Sufficient

Sufficient

Sufficient

Morikawa et al., 2018 [27]

Sufficient

Sufficient

Sufficient

Zhang et al., 2016 [28]

Sufficient

Sufficient

Sufficient

Heitz et al., 2009 e [29]

Sufficient

Sufficient

Sufficient

Berghoff et al., 2012 [30]

Sufficient

Sufficient

Sufficient

Brufsky et al., 2011 [31]

Sufficient

Sufficient

Sufficient

Kaplan et al., 2012 [33]

Sufficient

Sufficient

Sufficient

Jang et al., 2011 [34]

Sufficient

Insufficient

Sufficient

Kuba et al., 2014 [35]

Sufficient

Sufficient

Sufficient

Braccini et al., 2013 [36]

Sufficient

Sufficient

Sufficient

Niwinska et al., 2010 [39]

Sufficient

Sufficient

Sufficient

Sperduto et al., 2013 [37]

Sufficient

Insufficient

Sufficient

Martin et al., 2017 [38]

Insufficient

Sufficient

Sufficient

Anwar et al., 2021 [32]

Sufficient

Sufficient

Sufficient

Bergen et al., 2021 [19]

Sufficient

Sufficient

Sufficient

  1. a - Data attributes of exposure, outcomes (recording, objective measurement, validation) and important covariates/co-founders were assessed using 6 item checklist
  2. b – Scientific methods were assessed using 5 item checklist and focused on the following areas
  3. - New initiators of treatment
  4. - Concurrent comparators
  5. - Control of covariates/confounders/effect modifier
  6. - Control of immortal time bias
  7. - Analyses to evaluate the potential for bias for biased assessment